Ra Pharmaceuticals Announces Publication of Positive Preclinical Data with RA101295 for the Treatment of Escherichia Coli Sep...
20 July 2017 - 6:05AM
Business Wire
In Vitro and In Vivo Data Demonstrate
Protection Against Mortality and Multi-Organ Failure
Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage
biopharmaceutical company focusing on the development of
next-generation therapeutics for the treatment of
complement-mediated diseases, today announced the publication of in
vitro and in vivo data demonstrating that treatment of Escherichia
coli sepsis with RA101295 was associated with significant organ
protection and markedly reduced mortality. The article, “Inhibition
of Complement C5 Protects Against Organ Failure and Reduces
Mortality in a Baboon Model of Escherichia Coli Sepsis” (doi:
10.1073/pnas.1706818114) was published online in the Proceedings of
the National Academy of Sciences (PNAS).
Researchers evaluated the effect of RA101295, a macrocyclic
peptide inhibitor of complement component 5 (C5), in baboons
receiving lethal doses of E. coli. As compared with placebo,
treatment with RA101295 blocked sepsis-induced inflammation,
preserved endothelial cell function, decreased leukocyte
activation, and reduced overall mortality, while exhibiting no
detrimental effects on the clearance of bacteria.
“These data indicate that C5 inhibition could play an important
role in the treatment of bacterial sepsis and other acute systemic
inflammatory conditions, as well as providing further validation
for the use of Ra Pharma’s synthetic macrocyclic peptides for the
treatment of complement-mediated diseases,” said Doug Treco, PhD,
President and Chief Executive Officer of Ra Pharma. “While we
continue to advance our lead candidate, RA101495 for the treatment
of paroxysmal nocturnal hemoglobinuria (PNH), through its Phase 2
clinical program, we remain committed to exploring the versatility
of our proprietary compounds in acute and chronic conditions
arising from dysregulation of the complement system.”
Inhibition of C5 is a clinically-validated approach for the
treatment of complement-mediated disorders. Ra Pharma’s portfolio
includes drug candidates for several such disorders, including PNH,
myasthenia gravis (MG) and lupus nephritis (LN).
About Ra Pharmaceuticals
Ra Pharmaceuticals is a clinical stage biopharmaceutical
company focusing on the development of next-generation therapeutics
for complement-mediated diseases. The Company discovers and
develops peptides and small molecules to target key components of
the complement cascade. For more information, please
visit: www.rapharma.com.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding the
safety, efficacy and regulatory, pre-clinical and clinical progress
of our product candidates, including RA101295 and RA101495. All
such forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include
the risks that Ra Pharma’s product candidates, including RA101295
and RA101495, will not successfully be developed or commercialized;
the risk that initial data from the Company’s global Phase 2
clinical program evaluating RA101495 for the treatment of PNH may
not be indicative of final study results; the risk that initial
data from a limited number of patients may not be indicative of
results from the fully patient enrollment planned for such study;
as well as the other factors discussed in the “Risk Factors”
section in Ra Pharma’s most recently filed Annual Report on Form
10-K, as well as other risks detailed in Ra Pharma’s subsequent
filings with the Securities and Exchange Commission. There can
be no assurance that the actual results or developments anticipated
by Ra Pharma will be realized or, even if substantially realized,
that they will have the expected consequences to, or effects on, Ra
Pharma. All information in this press release is as of the date of
the release, and Ra Pharma undertakes no duty to update this
information unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170719006207/en/
Investors:Ra Pharmaceuticals, Inc.Jennifer Robinson,
617.674.9873jrobinson@rapharma.comorMedia:Argot PartnersEliza
Schleifstein, 917.763.8106eliza@argotpartners.com
Ra Pharmaceuticals (NASDAQ:RARX)
Historical Stock Chart
From Apr 2024 to May 2024
Ra Pharmaceuticals (NASDAQ:RARX)
Historical Stock Chart
From May 2023 to May 2024